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OBJECTIVES: Patients receiving treatment for tuberculosis are at risk of developing acute liver failure due to the
hepatotoxicity of antitubercular drugs. We aimed to describe our experience with liver transplantation from
deceased donors in this situation.
METHODS: We identified patients undergoing transplantation for acute liver failure due to antitubercular
drugs in our prospectively maintained database.
RESULTS: Of 81 patients undergoing transplantation for acute liver failure, 8 cases were attributed to
antitubercular drugs during the period of 2006-2016. Regarding the time of tuberculosis treatment until the
onset of jaundice, patients were on antitubercular drugs for a mean of 64.7 days (21-155 days). The model for
end-stage liver disease (MELD) score of patients ranged from 32 to 47 (median 38), and seven patients under-
went transplantation under vasopressors. The 1-year survival was 50%. Three patients died during the week
following transplantation due to septic shock (including a patient with acute liver failure due to hepatic/
disseminated tuberculosis), and the remaining patient died 2 months after transplantation due to pulmonary
infection. There were 2 cases of mild rejection and 1 case of moderate rejection. Of the surviving patients,
all were considered cured of tuberculosis after alternative drugs were given.
CONCLUSION: Patients arrived very sick and displayed poor survival after deceased donor transplantation.
KEYWORDS: Tuberculosis; Hepatic Insufficiency; Drug Toxicity; Survival; Liver Transplantation.
’ INTRODUCTION
Tuberculosis is one of the top 10 causes of death world-
wide, despite being a curable infectious disease (1). Brazil
is one of the countries with a high burden of tuberculosis,
with an estimated incidence of 44/100,000 pulmonary tuber-
culosis in 2014. Because Brazil is a large country, the incidence
of tuberculosis varies according to the area, city size, population
density and socioeconomic indicators (2).
The cornerstone of tuberculosis treatment consists of a
regimen containing rifampicin, isoniazid, pyrazinamide and
ethambutol. The first three drugs are potentially hepatotoxic (3),
and the incidence of hepatoxicity has been reported to vary
between 2% and 28% (4). More often, these drugs lead to an
asymptomatic increase in serum aminotransferase levels, but
acute liver failure (ALF) even after the discontinuation of the
drugs has also been reported (5). Antitubercular drug-induced
hepatotoxicity is related to an idiosyncratic reaction to the released
metabolites and can occur independently of the dose (4,6).
ALF is a life-threatening condition with variable mortality
rates, depending on etiology and age, among other factors
(7). Liver transplantation (LT) is the only treatment for cases
within previously established criteria (8). In Europe, 8% of LT
are due to ALF, and 18% of these cases are due to drug-
induced liver damage (7). LT for ALF due to antitubercular
drugs presents peculiarities for management and outcome
prediction that deserve to be better understood. Some pub-
lished case reports and series have described varying survival
rates after LT for ALF. Moreover, patients in this context may
present with a confounding symptom, as the disease itself can
present as diffuse hepatic infiltration, also known as granulo-
matous hepatitis leading to ALF (9).
In this study, we aimed to describe our experience with LT
for ALF resulting from the use of antitubercular drugs to aid
in the decision-making for LT in patients in this situation.
’ METHODS
For case identification, we initially identified all patients
listed for ALF in our informatized national list over a 10-yearDOI: 10.6061/clinics/2018/e344
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period (2006-2016). Afterwards, we consulted our prospec-
tively maintained database to identify cases in which drug
toxicity was the cause of ALF and finally consulted infor-
matized patient charts to identify all patients undergoing LT
for ALF related to tuberculosis treatment.
ALF management protocol
Patients referred to our unit with ALF are systematically
subjected to the following protocol: laboratory workup includ-
ing serologies for viral hepatitis, HIV, HTLV, toxoplasmosis,
cytomegalovirus, syphilis, Chagas, HCV RNA quantification,
autoimmune autoantibodies, factor V, and ABO typing, in
addition to routine hematological and biochemical exams; radio-
logical workup includes Doppler ultrasound of the upper
abdomen; procedures such as central line and intracerebral
monitoring are performed if indicated; and written consent is
obtained from the family for listing and transplantation.
Antimicrobial treatment includes cefotaxime and flucona-
zole. Post-transplantation prophylaxis includes ivermectin,
sulfametoxazol-trimetoprim, and preemptive approach for
cytomegalovirus.
Patients who met the previously established criteria (King’s
College or Clichy) were listed for LT (10,11).
The immunosuppression protocol consisted of 500 mg intra-
operative methylprednisolone, tapering until 20 mg prednisone
was reached, followed by weaning over 3 months. Tacrolimus
was initiated on the first post-operative day aiming at a serum
level of 8-10 ng/ml. Sodium mycophenolate was added if there
was renal insufficiency, and in this context, the target serum
level of tacrolimus was 5-8 ng/ml.
’ RESULTS
From 2006 to 2016, 81 patients underwent LT for ALF
at our institution. Fourteen (17.2%) cases were due to drug
toxicity, and of these, 8 were related to antitubercular drugs.
All eight patients were women, with a median age of
39 years (range 17-56). None of the patients had any history
of liver disease; three had hypertension, and one had hypo-
thyroidism as comorbidities.
Clinical and laboratory data
Six patients presented with the acute form of liver failure,
and two patients presented the hyperacute form according to
previous classifications (12). The interval between jaundice
and encephalopathy onset ranged from 2 to 27 days (mean
13.1 days). Regarding the grade of encephalopathy, 4 patients
were transplanted with West Haven grade II encephalopathy
(13), 2 had grade III, and 2 had grade IV encephalopathy.
On admission, the median liver functional values were as
follows: AST 459 U/L (167-1623 U/L); ALT 555 U/L (141-265
U/L); TB 22.9 mg/dL (6.21-44.2 mg/dL); INR 4.34 (1.7-10.7);
creatinine 0.72 mg/dL (0.42-1.74 mg/dL); model for end-stage
liver disease (MELD) score 34 (30-40); and factor V 25%
(13-31%).
The median MELD score immediately before transplanta-
tion was 38 (32-47). The median laboratory values immedi-
ately before transplantation were TB 23.2 mg/dL (11.4-39.3);
INR 3.33 (1.29-5.09); Creatinine 1.73 mg/dL (0.32-3.65 mg/dL);
and factor V 25% (15-36%).
After being listed as priority patients, the waiting time
until transplantation ranged from a few hours to 17 days
(median 4 days).
All eight patients had severe hepatic insufficiency, and five
patients underwent transplantation under mechanical ventila-
tion. Two patients required renal replacement therapy before
transplantation, and all of them did so after transplantation.
Six patients required vasopressors before transplantation.
Of the 8 transplanted patients, 4 had an additional active
infection at the time of transplantation, all of pulmonary site
(2 unknown etiology, 1 carbapenem-resistant Acinetobacter
baumanii and 1 ESBL-producing Klebsiella pneumoniae).
Pre- and post-transplantation tuberculosis data
Six patients had pulmonary tuberculosis; the remaining
two had ocular and bone tuberculosis. One patient diagnosed
with pulmonary tuberculosis was later diagnosed as having
disseminated disease that had infiltrated the lung, liver and
bowels. The diagnosis of tuberculosis was done by posi-
tive direct bacilloscopy in four patients, positive culture in
two, Mycobacterium tuberculosis PCR in one, and histological,
clinical and radiological characteristics in the remaining case
(Table 1). Regarding the time of tuberculosis treatment until
the onset of jaundice, patients were on antitubercular drugs
for a mean of 69 days (21-155 days) and a median of 34 days.
Four of the 8 transplanted patients received at least 2 months
of antitubercular treatment before transplantation. All patients
were using rifampicin and isoniazid; seven were on pyrazi-
namide; and six were using ethambutol at the beginning of
the symptoms.
After transplantation, patients received an alternative treat-
ment for tuberculosis based on ethambutol in 6 cases, levo-
floxacin in 6 cases, streptomycin in 2 cases, ciprofloxacin in
1 case, azithromycin in 1 case, and linezolid in 1 case. The
4 patients who were alive at one year after transplantation had
received alternative tuberculosis treatment for 6 months
(1 patient), 9 months (2 patients) and 1 year (1 patient). All were
considered cured, with no symptoms suggestive of recurrent
tuberculosis.
Outcome
The 1-year survival rate after the transplantation was 50%;
two deaths occurred at 1 and 7 days post-transplantation and
were related to sepsis and multiorgan failure after severe
hemodynamic instability; one patient died 2 months after the
procedure due to sepsis from pulmonary infection; and the
last patient presented with hepatomegaly on admission and
underwent LT for ALF due to antitubercular drugs after
1 month of treatment. Liver pathology showed a 1540-g liver
with granulomas with caseum. He died 2 days after the
transplantation due to disseminated disease that had infil-
trated the lung, liver and bowels. All 4 patients who died
were on vasopressor drugs pre-transplantation; 1 patient had
grade II encephalopathy, and the others had grade III or IV
encephalopathy, with a MELD score ranging from 33 to 47.
Of the 4 patients with 1-year survival, only 2 were on vaso-
pressors at the time of transplantation; 3 had grade II
encephalopathy, and 1 had grade IV encephalopathy, with a
MELD score ranging from 32 to 42. The surviving patients
were followed up for a mean of 1991 days.
Pathology
On liver pathology, organ weight varied from 463.9 g to
1540 g. Histology showed massive and sub-massive hepatic
necrosis in all cases, but in one patient, the necrosis was
2
ALF due to antitubercular drugs
Martino RB et al.
CLINICS 2018;73:e344
present in a micronodular liver cirrhosis background. In this
case and another one, granuloma with caseum was found.
’ DISCUSSION
To the best of our knowledge, this study has the largest
number of transplanted patients in a single center for ALF
due to antitubercular drugs. Previously published studies
include series of cases and isolated case reports (14-17), and
our series may contribute to the current literature regarding
patient characteristics before transplantation and manage-
ment of tuberculosis and outcome after transplantation.
As ours is a national reference center, 7 out of the 8 patients
were referred in critical condition from other hospitals. More
than half of the patients underwent transplantation under
both ventilatory and circulatory support, which could explain
the low 1-year survival rate of 50% even for LT due to ALF,
which is typically worse than LT for chronic liver disease (18,25).
Compared to the patients who had favorable outcomes, the
patients who had poor outcomes underwent surgery on
vasopressor drugs (50 vs 100%) and had grade III or IV
encephalopathy (1 vs 3). Two of those patients with worse
outcomes, in fact, had bad indications for the procedure. One
had disseminated tuberculosis, and the other probably had
an acute-on-chronic liver disease triggered by antitubercular
drugs. The survival rate in our report is equivalent to the one
described by Ichai et al. (50%), which was, until recently,
the study with the largest number of transplanted patients in
the same context in a single center (14). Patients with ALF are
often in critical conditions, and some of them are very young.
There are no current well-established factors that can predict
the outcomes after transplantation. Despite the effort of some
authors, this issue remains to be better understood (19,20), and
as some authors suggest, the critical decision for transplantation
should be made on a case-by-case basis (21).
A recent comprehensive review reported on 19 trans-
planted individuals without known liver disease with good
long-term survival rates – however, 6 of these patients were
from the Ichai cohort, and 10 were single case reports (17).
Based on these data, we can conclude that in general, single
case reports describe cases with favorable outcomes, and
authors are usually less motivated to publish cases with
negative results, and therefore the reported survival rate in
the review may have been overestimated. Although another
recently published paper demonstrated excellent survival
rates for 6 individuals undergoing emergency living donor
transplantation in the same context, little information is given
regarding pre-transplantation characteristics of the patients and
life support, with a mean MELD score of 30.1 (compared to the
mean score of 38 in our cohort). The 6 transplanted individuals
came from a pool of 19 patients with ALF, and possibly those
with better clinical parameters were given the chance of living
donor transplantations, considering the risks for the donor (15).
Another recent paper described a good survival rate of 71.4% in
7 patients undergoing living donor transplantations in India,
with a median follow-up of 22 months (16). Although the
authors did not mention any patient who were unfit for
transplantations, patients went to the procedure very sick, with
a mean MELD score greater than 35.
Once patients are referred to our clinic under antituber-
cular drugs, it may be difficult to differentiate whether hepatic
damage is due to therapy or related to liver infiltration of
disseminated tuberculosis. Additionally, it seems that the prog-
nosis is completely different under these two circumstances.Ta
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In their series, Ichai et al. (14) also reported one patient who
died after the LT due to disseminated tuberculosis, and similar
cases are described in single case reports, mostly post-mortem
(9,22-24). In the described cases, hepatomegaly may be a signal
of a disseminated disease into the liver rather than liver
damage caused by drugs.
Treatment after transplantation did not include the pos-
sible causative hepatotoxic drug, and alternative regimens
were capable of leading to cure in 100% of the surviving
cases. Other studies have reported similar findings, despite
the recommendation that any mycobacterial infection should
be optimally treated with documented microbiologic and
radiological resolution before transplantation is considered (26).
One major difficulty in administering antitubercular therapy
to transplantation patients is drug-drug interactions involving
rifampin (27). This drug and, to a lesser degree, isoniazid
induces the metabolism of tacrolimus via the induction of the
cytochrome P450 pathway, and thus the incidence of graft
rejection may be significant in solid organ transplantation
recipients.
There are some limitations to our study. It is a single-center
series, with a possible bias of patients with more severe
disease undergoing LT. Moreover, the number of cases
described is small.
In conclusion, patients were very sick at the time of trans-
plantation and displayed poor survival after deceased donor
transplantation. Except for the case in which the patient died
of disseminated tuberculosis, fatal outcome was not related
to tuberculosis but to complications of the transplantation
performed in patients in severe clinical conditions. Current
literature is lacking more sensitive diagnostic tools to predict
outcomes in ALF that can help avoid futile procedures.
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